| CPC C07D 513/04 (2013.01) [C07D 215/12 (2013.01); C07D 235/14 (2013.01); C07D 239/74 (2013.01); C07D 241/42 (2013.01); C07D 263/56 (2013.01); C07D 307/81 (2013.01); C07D 403/06 (2013.01); C07D 405/08 (2013.01); C07D 413/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/048 (2013.01); C07D 491/052 (2013.01); C07D 498/04 (2013.01)] | 20 Claims |
|
1. A compound of formula (II-A-1):
 or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt thereof, wherein:
L is methylene optionally substituted with one or more C1-6alkyl;
X1 is C, and X1 is taken together with R1 and the atoms to which they are attached, to form a 5 to 6 membered heteroarylfused to ring A;
wherein the 5 to 6 membered heteroaryl is optionally substituted with one or more Rt,
wherein Rt is independently, at each occurrence, selected from the group consisting of halo, C1-15 alkyl, haloC1-15 alkyl, C6-20aryl, 5 to 15 membered heteroaryl, C3-20cycloalkyl, 3 to 15 membered heterocyclyl, —OH, —CN, oxo, C1-15 alkoxy, —NRdCORe, —CONRdRe, —SO2Rd, —SO2NRdRe, —NRdSO2Re, and —NRdRe; and
wherein Rd and Re are each independently H or C1-6alkyl, and wherein the C1-6alkyl of Rd or Re is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, —OH and —CN;
X2 is CRs, wherein Rs is selected from the group consisting of H, halo, C1-15alkyl, hydroxylC1-6alkynyl, C6-20aryl, 5 to 15 membered heteroaryl, C3-20cycloalkyl, 3 to 15 membered heterocyclyl, —OH, —CN, C1-15alkoxy, —NRdCORe, —CONRdRe, —SO2Rd, —S(O)NHRd, —SO2NRdRe, —NRdSO2Re, and —NRdRe;
wherein the C1-15alkyl and C1-15alkoxy of Rs are each independently optionally substituted with one or more Rt1, wherein Rt1 is independently at each occurrence halo, oxo, —OH, —CN, 5-6 membered heteroaryl, or —NRdRe, wherein Rd and Re are each independently H or C1-6alkyl, and wherein the C1-6alkyl of Rd or Re is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, —OH and —CN; and
wherein the C6-20aryl, 5 to 15 membered heteroaryl, C3-20cycloalkyl, and 3 to 15 membered heterocyclyl of Rs are each independently optionally substituted with one or more Rt2, wherein Rt2 is independently at each occurrence selected from the group consisting of halo, oxo, —OH, —CN and C1-6alkyl; and
wherein Rd and Re are each independently H or C1-6alkyl, and wherein the C1-6alkyl of Rd or Re is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, —OH and —CN;
X3 is CH;
R2 is halo; S(Ry)5, wherein each Ry is halo; or C1-6alkoxy optionally substituted with one or more halo; R3 is H or C1-6alkyl; and
Z is —OH, —NRdRe, C1-6alkoxy, —C(O)Ra, or —S(O)2Rb,
wherein Rd and Re are each independently H or C1-6alkyl, and wherein the C1-6alkyl of Rd or Re is optionally substituted with one or more substituents selected from the group consisting of halo, oxo, —OH and —CN;
Ra and Rb are each independently i) C2-6alkenyl optionally substituted with one or more substituents selected from the group consisting of deuterium, C1-6alkyl, hydroxyl C1-6alkyl, halo and haloC1-6alkyl; ii) C1-6alkyl, optionally substituted with one or more halo; or iii) cyclobutenyl or bicyclobutanyl.
|